Abstract
Prostate cancer (PCa) is one of the common malignancies in male adults. In the era of precision medicine, many other novel agents targeting advanced prostate cancer, especially metastatic castration-resistant prostate cancer (mCRPC), are currently being evaluated. Among all these candidate therapies, poly-ADP ribose polymerase (PARP) inhibitors targeting DNA damage response (DDR) pathway has proven improving survival outcomes in clinical trials. In this review, we focus on recent advances in biology and clinical implication of DDR pathway and aim to discuss the latest results in advanced prostate cancer, especially mCRPC.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424
Fitzmaurice C, Abate D, Abbasi N et al (2019) Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol 5(12):1749–1768
Parker C, Lewington V, Shore N et al (2018) Targeted alpha therapy, an emerging class of cancer agents: a review. JAMA Oncol 4(12):1765–1772
Ritch CR, Cookson MS (2016) Advances in the management of castration resistant prostate cancer. BMJ (Clinical Research ed) 355:i4405
Nuhn P, De Bono JS, Fizazi K et al (2019) Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol 75(1):88–99
Almassi N, Reichard C, Li J et al (2018) HSD3B1 and response to a nonsteroidal CYP17A1 inhibitor in castration-resistant prostate cancer. JAMA Oncol 4(4):554–557
Miller K, Carles J, Gschwend JE et al (2018) The Phase 3 COU-AA-302 Study of abiraterone acetate plus prednisone in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: stratified analysis based on pain, prostate-specific antigen, and gleason score. Eur Urol 74(1):17–23
Fizazi K, Tran N, Fein L et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377(4):352–360
Saito K, Fujii Y (2018) Antitumor activity and safety of enzalutamide after abiraterone acetate: seeking the optimal treatment sequence for castration-resistant prostate cancer patients. Eur Urol 74(1):46–47
Anker MS, Lehmann LH, Anker SD (2018) Enzalutamide in castration-resistant prostate cancer. N Engl J Med 379(14):1380
Antonarakis ES, Tagawa ST, Galletti G et al (2017) Randomized, noncomparative, phase II trial of early switch from docetaxel to cabazitaxel or vice versa, with integrated biomarker analysis, in men with chemotherapy-naïve, metastatic, castration-resistant prostate cancer. J Clin Oncol 35(28):3181–3188
Rouyer M, Oudard S, Joly F et al (2019) Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort. Br J Cancer 121(12):1001–1008
Hansen AR, Massard C, Ott PA et al (2018) Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol 29(8):1807–1813
Gulley JL, Madan RA, Pachynski R et al (2017) Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment. J Natl Cancer Inst 109(4):djw261
Lang SH, Swift SL, White H et al (2019) A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer. Int J Oncol 55(3):597–616
Ashworth A, Lord CJ (2018) Synthetic lethal therapies for cancer: what’s next after PARP inhibitors? Nat Rev Clin Oncol 15(9):564–576
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
Chang HHY, Pannunzio NR, Adachi N et al (2017) Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol 18(8):495–506
Caldecott KW (2008) Single-strand break repair and genetic disease. Nat Rev Genet 9(8):619–631
Her J, Bunting SF (2018) How cells ensure correct repair of DNA double-strand breaks. J Biol Chem 293(27):10502–10511
Schlacher K, Christ N, Siaud N et al (2011) Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell 145(4):529–542
Clauson C, Schärer OD, Niedernhofer L (2013) Advances in understanding the complex mechanisms of DNA interstrand cross-link repair. Cold Spring Harb Perspect Biol 5(10):a012732
Zhao W, Steinfeld JB, Liang F et al (2017) BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing. Nature 550(7676):360–365
Rottenberg S, Jaspers JE, Kersbergen A et al (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 105(44):17079–17084
Moynahan ME, Cui TY, Jasin M (2001) Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 61(12):4842–4850
Alli E, Sharma VB, Hartman AR et al (2011) Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacol 11:7
Jensen RB, Carreira A, Kowalczykowski SC (2010) Purified human BRCA2 stimulates RAD51-mediated recombination. Nature 467(7316):678–683
Kuchenbaecker KB, Mcguffog L, Barrowdale D et al (2017) Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 109(7):djw302
Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130
Mavaddat N, Peock S, Frost D et al (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105(11):812–822
Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70
Teixeira LA, Candido Dos Reis FJ (2020) Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review. J Clin Pathol 73(4):191–196
Li M, Yu X (2013) Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation. Cancer Cell 23(5):693–704
Rezaeian AH, Li CF, Wu CY et al (2017) A hypoxia-responsive TRAF6-ATM-H2AX signalling axis promotes HIF1α activation, tumorigenesis and metastasis. Nat Cell Biol 19(1):38–51
Miller RM, Nworu C, Mckee L et al (2020) Development of an immunohistochemical assay to detect the ataxia-telangiectasia mutated (ATM) protein in gastric carcinoma. Appl Immunohistochem Mol Morphol 28(4):303–310
Jette NR, Radhamani S, Arthur G et al (2019) Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells. Br J Cancer 121(7):600–610
Foote KM, Nissink JWM, Mcguire T et al (2018) Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) Kinase with application as an anticancer agent. J Med Chem 61(22):9889–9907
Bradbury A, Hall S, Curtin N et al (2019) Targeting ATR as cancer therapy: a new era for synthetic lethality and synergistic combinations? Pharmacol Ther 207:107450
Pritchard CC, Mateo J, Walsh MF et al (2016) Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 375(5):443–453
Bancroft EK, Page EC, Castro E et al (2014) Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol 66(3):489–499
Castro E, Goh C, Olmos D et al (2013) Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 31(14):1748–1757
Na R, Zheng SL, Han M et al (2017) Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol 71(5):740–747
Castro E, Romero-Laorden N, Del Pozo A et al (2019) PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol 37(6):490–503
Carter H, Helfand B, Mamawala M et al (2019) Germline mutations in ATM and BRCA1/2 are associated with grade reclassification in men on active surveillance for prostate cancer. Eur Urol 75(5):743–749
Robinson D, Van Allen EM, Wu YM et al (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161(5):1215–1228
Abida W, Armenia J, Gopalan A et al (2017) Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol 2017:10
Hart SN, Ellingson MS, Schahl K et al (2016) Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. BMJ Open 6(4):e010332
Beltran H, Yelensky R, Frampton GM et al (2013) Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 63(5):920–926
Grasso CS, Wu YM, Robinson DR et al (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487(7406):239–243
Wl K (2015) PARPs and ADP-ribosylation: 50 years … and counting. Mol Cell 58(6):902–910
El-Khamisy SF, Masutani M, Suzuki H et al (2003) A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res 31(19):5526–5533
Luo X, Kraus WL (2012) On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev 26(5):417–432
Hegan DC, Lu Y, Stachelek GC et al (2010) Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci U S A 107(5):2201–2206
Schiewer MJ, Knudsen KE (2014) Transcriptional roles of PARP1 in cancer. Mol Cancer Res 12(8):1069–1080
Langelier MF, Eisemann T, Riccio AA et al (2018) PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification. Curr Opin Struct Biol 53:187–198
Helleday T (2016) PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations. Ann Oncol 27(5):755–757
Kaufman B, Ronnie S-F, Schmutzler Rita K et al (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33(3):244–250
Mateo J, Carreira S, Sandhu S et al (2015) DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 373(18):1697–1708
Mateo J, Porta N, Bianchini D et al (2019) Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 21(1):162–174
Lafargue CJ, Molin GZD, Sood AK et al (2019) Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol 20(1):e15–e28
Clarke N, Wiechno P, Alekseev B et al (2018) Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 19(7):975–986
Heyman B, Jamieson C (2019) To PARP or not to PARP?-Toward sensitizing acute myeloid leukemia stem cells to immunotherapy. EMBO J 38(21):e103479
Césaire M, Thariat J, Candéias SM et al (2018) Combining PARP inhibition, radiation, and immunotherapy: a possible strategy to improve the treatment of cancer? Int J Mol Sci 19(12):3793
Evan Y, Yu MC, Margitta R et al (2019) Keynote-365 cohort a: pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol 37(7_suppl):145
Karzai F, Vanderweele D, Madan RA et al (2018) Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer 6(1):141
Sabatucci I, Maltese G, Lepori S et al (2018) Rucaparib: a new treatment option for ovarian cancer. Expert Opin Pharmacother 19(7):765–771
Abida W, Bryce AH, Vogelzang NJ et al (2019) Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2. J Clin Oncol 37(15_suppl):5031
Ison G, Howie LJ, Amiri-Kordestani L et al (2018) FDA Approval summary: niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy. Clin Cancer Res 24(17):4066–4071
Sandhu SK, Schelman WR, Wilding G et al (2013) The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 14(9):882–892
Smith MR, Kaur SS, Kevin KW et al (2019) Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): preliminary results of GALAHAD. J Clin Oncol 37(7_suppl):202
Boussios S, Karihtala P, Moschetta M et al (2020) Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. Invest New Drugs 38(1):181–193
Tuli R, Shiao SL, Nissen N et al (2019) A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. EBioMedicine 40:375–381
Owonikoko TK, Dahlberg SE, Sica GL et al (2019) Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study. J Clin Oncol 37(3):222–229
Loibl S, O’shaughnessy J, Untch M et al (2018) Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 19(4):497–509
Hussain M, Anthony CM, Slovin Susan F et al (2012) Pilot study of veliparib (ABT-888) with temozolomide (TMZ) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 30(5_suppl):224–224
Pahuja S, Joseph AL, Prakash BC et al (2015) Preliminary activity of veliparib (V) in BRCA2-mutated metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 33(7_suppl):170
Hussain M, Daignault-Newton S, Twardowski PW et al (2018) Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012. J Clin Oncol 36(10):991–999
Murai J, Huang SY, Das BB et al (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72(21):5588–5599
Hoy SM (2018) Talazoparib: first global approval. Drugs 78(18):1939–1946
De Bono JS, Higano Celestia S, Fred S et al (2019) TALAPRO-1: an open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair (DDR) defects and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on greater than or equal to one novel hormonal therapy (NHT). J Clin Oncol 37(7_suppl):TPS342–TPS342
Friedlander M, Meniawy T, Markman B et al (2019) Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. Lancet Oncol 20(9):1306–1315
Mcpherson LA, Shen Y, Ford JM (2014) Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells. Cancer Lett 343(2):217–223
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Xu, C., Mao, S., Jiang, H. (2020). Recent Advances in DNA Repair Pathway and Its Application in Personalized Care of Metastatic Castration-Resistant Prostate Cancer (mCRPC). In: Huang, T. (eds) Precision Medicine. Methods in Molecular Biology, vol 2204. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0904-0_7
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0904-0_7
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0903-3
Online ISBN: 978-1-0716-0904-0
eBook Packages: Springer Protocols